Gilles Houvenaeghel is an expert in Oncology at Institut Paoli-Calmettes (France). As of September 2026, ScienceLeadR ranks Gilles Houvenaeghel in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Gilles Houvenaeghel has authored 410 publications, the most recent in 2026, and is an investigator in 10 clinical trials. SLR score: 1,059 (community average: 125). How the SLR is computed.

LeadR Profile

Gilles Houvenaeghel Institut Paoli-Calmettes France
1 059 ScienceLeadR Reputation 1059
Network Map

Oncology

Subspecialties: Gynecology - Surgery - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1990 - 2026

Source: PubMed

Institut Paoli-Calmettes

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 410

Citations

Citations: 10 570 1st author: 86 Last author: 64 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Could systematic ileostomy decrease anastomotic leakage after modified posterior exenteration in advanced stage ovarian cancer patients? retrospective cohort analysis of two referral centers.
PMID 42061050 — reproduction, ovary, neoplasms, obstetrics, ovarian neoplasms, multivariate analysis, gynecology, peritoneal neoplasms, anastomotic leak, ileostomy
Eur J Obstet Gynecol Reprod Biol20260
Feasibility and safety of repeat breast-conserving surgery with intraoperative irradiation for local breast carcinoma recurrences: A phase 2 trial.
PMID 42001960 — radiotherapy, mastectomy, estrogens, safety, breast neoplasms, fibrosis, receptors, estrogen, re-irradiation, breast, therapeutics
Radiother Oncol20260
Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti-PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer.
PMID 40626883 — cells, triple negative breast neoplasms, breast neoplasms, neoplasms, phenotype, breast, therapeutics
Cancer Immunol Res20250
[Oncoplasty and immediate breast reconstruction].
PMID 40473502 — mastectomy, neoplasms, mammaplasty, breast, therapeutics
Bull Cancer20250
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
PMID 40329152 — breast neoplasms, nomograms, neoplasms, breast
Breast Cancer Res Treat20250

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 6
Phase 3 3
Phase 2 1

By status:

Completed 4
Active not recruiting 2
Recruiting 2
Not yet recruiting 1
Unknown 1

By type:

Interventional 8
Observational 2

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 1
multicentricup10 3

Main Topics

LeadR Networks

Main global connection map